Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights


A question of balance: the value of an integrated approach to AAV US and DS bioprocessing

Tarik Senussi


Tarik Senussi is the Head of Process Development at Gyroscope Therapeutics Ltd. Tarik joined Gyroscope in February 2017 and has been working on developing platform processes for rAAV manufacture from both suspension and adherent platforms. Prior to Joining Gyroscope Tarik was at GSK, as Lead Upstream Process Development Scientist, where he was responsible for establishing the upstream process development platform and team for the production of viral vectors. During this time, Tarik undertook support of the first ex-vivo cell and gene therapy to gain commercial approval and development of a suspension platform to progress pipeline assets. Prior to that Tarik worked at Medimmune Ltd as a scientist II and Lonza Biologics Ltd as a senior R&D scientist where he supported cell culture and fermentation sciences and new product development respectively. Tarik supported pipeline assets (MEDI8968, MEDI7136 & MEDI8968) as well as testing and embedding the first ambr-15 48 parallel bioreactor chilled system in cell line development at Medimmune Ltd. Whilst at Lonza Tarik focused on new technology development and evaluations and helped to commercialise the Potelligent® CHOK1SV cell line for monoclonal antibody production. Tarik holds a BSc in Cell Biology and a PhD in Biochemical Engineering both from University College London.

DOI: 10.18609/cgti.2019.019
Citation: Cell & Gene Therapy Insights 2019; 5(S2), 221-226.
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog